

## Grifols collaborates with CRAM on a project to bring marine conservation closer to hospitalized children

- *'A Sea of Hope' is an initiative aimed at transforming the hospital environment into a space where patients can learn and disconnect from their daily routine.*
- *The Vall d'Hebron and Sant Joan de Déu hospitals are hosting the project, in which nearly one hundred children have participated.*
- *Through participatory workshops, the young participants become part of a marine rescue team, simulating the recovery of turtles affected by waste or the rescue of a dolphin.*

**Barcelona, June 1<sup>st</sup>, 2026** – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, together with CRAM (Fundació per a la Conservació i Recuperació d'Animals Marins), has launched 'A Sea of Hope', an initiative aimed at bringing marine conservation closer to hospitalized children. The goal is to transform the hospital environment into a space for learning, participation, and a break from daily routines.

Through workshops led by CRAM professionals, the children become part of a marine rescue team, simulating the recovery of turtles affected by waste or the rescue of a dolphin through activities adapted to each group. In addition, the project aims to raise awareness among young participants about the impact of plastics in the ocean.

Vall d'Hebron and Sant Joan de Déu hospitals in Barcelona have hosted the initiative, in which nearly one hundred children have participated across a total of 36 workshops. The activities have taken place in different hospital areas, ranging from pediatrics to oncology, dialysis, mental health, and the intensive care unit. In spaces such as La Casa de Sofia, dedicated to children with rare diseases and complex chronic conditions, the initiative has helped foster learning in challenging environments.

CRAM has highlighted that "the workshops have created spaces for disconnection, learning, and motivation within the hospital environment, and the response from both participants and hospital professional teams has been excellent."

They also emphasized that "thanks to the collaboration with Grifols, we have been able to carry out this initiative by adapting the activities to the needs of the different hospitals. We have reached children and adolescents in particularly sensitive situations and achieved a very positive impact both educationally and emotionally."

'A Sea of Hope' is one of the initiatives the company promotes through its Grifols Social Initiatives (GSI) program. Over the past year, Grifols has collaborated with more than 20 social projects in the communities where it operates in Spain, such as Sant Cugat del Vallès, Parets del Vallès, and Barcelona.

## About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols focuses on treating conditions centered on six core therapeutic areas: immunology, neurology, pulmonology, hematology, hepatology and intensive care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's most diversified with more than 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 25,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit [www.grifols.com](http://www.grifols.com)

## MEDIA CONTACTS:

### Grifols Press Office

[media@grifols.com](mailto:media@grifols.com)

Phone: +34 93 571 00 02

## INVESTORS

### Investors Relations & Sustainability

[inversores@grifols.com](mailto:inversores@grifols.com) - [investors@grifols.com](mailto:investors@grifols.com)

[sostenibilidad@grifols.com](mailto:sostenibilidad@grifols.com) - [sustainability@grifols.com](mailto:sustainability@grifols.com)

Phone: +34 93 571 02 21

## LEGAL DISCLAIMER

*The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the foreseeable impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.*